Incyte will spend $2 billion to acquire a biotechnology company focused on blood disease treatment

Mars Finance News: June 7 - According to reports, U.S. stock-listed pharmaceutical company Incyte is about to acquire a biotechnology company focused on blood disease treatment for up to $2 billion.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned